Transcode Therapeutics (RNAZ) Income from Continuing Operations (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Income from Continuing Operations came in at 17553762.0 in Q1 2026, down 45.25% YoY from 32060210.31 in Q1 2025, and down 9.8% on a QoQ basis from 15986571.0 in Q4 2025.
Transcode Therapeutics (RNAZ) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Income from Continuing Operations data on file, last reported at 17553762.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 45.25% year-over-year to 17553762.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 42402546.0 (down 72.38% YoY) and the FY2025 annual result came in at 34435008.0, down 105.52% from the prior year.
- Income from Continuing Operations fell to 17553762.0 in Q1 2026, from 15986571.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2276423.0 in Q3 2024 to a low of 17553762.0 in Q1 2026.
- A 5-year average of 6513034.18 and a median of 5152218.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 600.38% — and 2024, when it jumped 58.46%.
- Tracing RNAZ's Income from Continuing Operations over 5 years: stood at 5502329.0 in 2022, then advanced by 25.31% to 4109777.0 in 2023, then retreated by 23.7% to 5083877.0 in 2024, then plunged by 214.46% to 15986571.0 in 2025, then declined by 9.8% to 17553762.0 in 2026.
- The last three Income from Continuing Operations figures came in at 17553762.0 (Q1 2026), 15986571.0 (Q4 2025), and 4629512.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | -6.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.55 Mn |
| Dec 31, 2025 | -15.99 Mn |
| Sep 30, 2025 | -4.63 Mn |
| Jun 30, 2025 | -4.23 Mn |
| Mar 31, 2025 | -12.09 Mn |
| Dec 31, 2024 | -5.08 Mn |
| Sep 30, 2024 | -2.28 Mn |
| Jun 30, 2024 | -5.15 Mn |
| Mar 31, 2024 | -3.40 Mn |
| Dec 31, 2023 | -4.11 Mn |
| Sep 30, 2023 | -5.48 Mn |
| Jun 30, 2023 | -5.31 Mn |
| Mar 31, 2023 | -5.01 Mn |
| Dec 31, 2022 | -5.50 Mn |
| Sep 30, 2022 | -5.64 Mn |
| Jun 30, 2022 | -5.75 Mn |
| Mar 31, 2022 | -3.52 Mn |
| Dec 31, 2021 | -2.91 Mn |
| Sep 30, 2021 | -7.15 Mn |
| Jun 30, 2021 | 2.77 Mn |